Virology

Infinity Bio Launches Next-Generation Antibody Profiling Platform Utilizing MIPSA Technology

Retrieved on: 
Wednesday, January 31, 2024
Other Health, Stem Cells, Pharmaceutical, Oncology, General Health, Medical Devices, Infectious Diseases, Hospitals, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Nursing, Research, Health, Inflammation, Protein, Immunity, Infinity, Immune system, Harvard University, DNA, Clinical trial, Disease, Biomarker, Virus, Self-assembly, Antibody, Biomarker discovery, Virology, Pathology, Doctor of Philosophy, Autoimmunity, Blood, CSO, Therapy, Associate, Allergy, Area studies, Vaccine

Infinity Bio , Inc. announces its new antibody profiling platform, leveraging Molecular Indexing of Proteins by Self-Assembly ( MIPSA ) technology.

Key Points: 
  • Infinity Bio , Inc. announces its new antibody profiling platform, leveraging Molecular Indexing of Proteins by Self-Assembly ( MIPSA ) technology.
  • Infinity Bio's proprietary MIPSA technology is a leap forward in antibody profiling.
  • This capability places Infinity Bio at the forefront of disease research, biomarker discovery, monoclonal antibody optimization, vaccine development, and therapeutic advancement.
  • H. Benjamin Larman, Ph.D., co-founder and CSO of Infinity Bio and Associate Professor of Pathology at Johns Hopkins School of Medicine, explains, “Infinity Bio was formed to elucidate each individual’s portfolio of antibodies.

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023

Retrieved on: 
Wednesday, January 31, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Virology, Immunology, Webcast, Medication

Enanta management will host a conference call at 4:30 p.m.

Key Points: 
  • Enanta management will host a conference call at 4:30 p.m.
  • ET to discuss these results and provide an update on the company’s business and research and development pipeline.
  • It is recommended that participants register one day in advance or at a minimum of 30 minutes before the call.
  • A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

Lantheus Announces CEO Succession Plan

Retrieved on: 
Tuesday, January 23, 2024
Virology, Bristol Myers Squibb, Patient, Chairperson, Neurology, Prostate cancer, Yamaha, PET, Intelligence, Chair, King Pharmaceuticals, Cancer, Acquisition, LNTH, PSMA, Therapy, College, Senior, Growth, Management

BEDFORD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Company has appointed Brian Markison, current Board Chair and industry veteran, to the position of Chief Executive Officer (CEO), effective as of March 1, 2024. He will also continue as a member of Lantheus’ Board of Directors, where he has served for the past 11 years. Mary Anne Heino, who has successfully led and grown the Company for the past nine years, will retire as CEO on March 1, 2024 and assume the role of Chair of the Board of Directors as part of a deliberate CEO succession process. As part of this leadership transition, Mr. Markison will assume the role of Executive Chair of the Board immediately until his CEO appointment in March, and Board Member Julie McHugh will become Lead Independent Director effective immediately.

Key Points: 
  • He will also continue as a member of Lantheus’ Board of Directors, where he has served for the past 11 years.
  • Mary Anne Heino, who has successfully led and grown the Company for the past nine years, will retire as CEO on March 1, 2024 and assume the role of Chair of the Board of Directors as part of a deliberate CEO succession process.
  • “On behalf of the Lantheus Board of Directors, I would like to sincerely thank Mary Anne for her remarkable leadership and contributions that helped drive Lantheus’ success throughout her tenure as CEO,” said Ms. McHugh.
  • “I want to thank the Board of Directors for this tremendous opportunity to lead Lantheus as CEO,” said Brian Markison.

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Retrieved on: 
Monday, January 8, 2024
LNP, RNA interference, AASLD, Virology, HBV, Vaccine, Court, Nivolumab, Congress, Clinical trial, Pharmacokinetics, PD, Expert witness, Arbutus, COVID-19, EASL, CFBV, Interim, Investment, Patient, Safety, HBsAg, PD-L1, Pharmaceutical industry

Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.

Key Points: 
  • Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.
  • Arbutus plans to announce end-of-treatment data from this portion of the trial in the first half of 2024.
  • Arbutus expects to report preliminary data from the healthy subject portion of this clinical trial, including target engagement and receptor occupancy data, in the first half of 2024.
  • With respect to the Moderna lawsuit, fact discovery is currently on-going with the claim construction hearing scheduled for February 8, 2024.

Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination

Retrieved on: 
Friday, January 5, 2024
Virology, Business analyst, Acquisition, Form, Transaction, Special, Semper paratus, LGST, Therapy, Security (finance), Neurology

The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion.

Key Points: 
  • The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion.
  • Tevogen Bio is an advanced-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
  • New York, NY, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Inc (“Tevogen Bio”), an advanced-stage specialty immunotherapy biotech pioneer and Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced that the Securities and Exchange Commission ("SEC") has declared effective the registration statement on Form S-4 (the "Registration Statement") filed by Semper Paratus in connection with Tevogen Bio and Semper Paratus’s previously announced proposed business combination (the “Business Combination” or the “Transaction”).
  • Semper Paratus will hold an extraordinary general meeting of its stockholders (the “Special Meeting”) at which shareholders will be asked to consider and vote upon proposals to approve the Business Combination and related matters.

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Virology, Conference, Heart, Partnership, RSV, FDA, Medication, Chronic obstructive pulmonary disease, Disease, Hepatitis, KIT, Viral load, ADME, Pharmacokinetics, Asthma, COVID-19, CSU, Webcast, Patient, Safety, Therapy, Fast Track, Pharmaceutical industry

Our foundational capabilities in virology and small molecule drug development transition well to immunology, an adjacent field where we can leverage our core strengths.

Key Points: 
  • Our foundational capabilities in virology and small molecule drug development transition well to immunology, an adjacent field where we can leverage our core strengths.
  • The company has developed novel, potent and selective oral inhibitors of KIT, which are now being optimized in preclinical development.
  • Enanta will present new preclinical data on its prototype KIT inhibitor at the J.P. Morgan Conference and is targeting the selection of a development candidate in 2024.
  • A replay of the webcast will be available following the presentation and will be archived for approximately 60 days.

Harvey J. Berger, M.D. Joins Kojin Therapeutics as Chairman, President, and Chief Executive Officer

Retrieved on: 
Wednesday, January 3, 2024
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Ferroptosis, Immunology, Cameron Boyce, Broad Institute, Drug discovery, Autoimmune disease, Science, Virology, Janssen Pharmaceuticals, Research, Chemical biology, MIT, Dana–Farber Cancer Institute, Apoptosis, Conditional sentence, Yale School of Medicine, Bayer, Yang, Therapy, Cancer, Investment, Polaris Partners, ARIAD Pharmaceuticals, Medicine, Harvard University, Yale New Haven Hospital, Scripps Research, Patient, Cardiovascular disease, Colgate University, Harvard Medical School, Organization, Yale school, Wolf Prize, Pharmaceutical industry

Kojin Therapeutics, Inc., a pioneer in cell-state and ferroptosis biology and cutting-edge drug discovery, today announced the appointment of Harvey J. Berger, M.D.

Key Points: 
  • Kojin Therapeutics, Inc., a pioneer in cell-state and ferroptosis biology and cutting-edge drug discovery, today announced the appointment of Harvey J. Berger, M.D.
  • as its new chairman, president, and chief executive officer.
  • He founded ARIAD Pharmaceuticals and led the company from a start-up to a fully integrated global oncology company.
  • Kojin co-founder Professor Stuart Schreiber stated, “We are thrilled to welcome Dr. Berger, a long-time colleague and collaborator, as Kojin’s new chief executive.

Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

Retrieved on: 
Thursday, November 30, 2023
Computer science and engineering, Marketing, Glooko, IP Group, Drug discovery, AstraZeneca, Eli Lilly, Business administration, Molecular biology, Annual general meeting, Retirement, Virology, Eli Lilly and Company, Therapy, American Red Cross, Head, Duke University, University, Obesity, Doctor of Philosophy, Mechanical, Management

20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company’s board of directors.

Key Points: 
  • 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company’s board of directors.
  • It is expected that Enrique Conterno and Elaine Sullivan will stand for election to Zealand Pharma’s board of directors at the company’s 2024 Annual General Meeting.
  • “As board observes, Enrique and Elaine collectively bring decades of international pharmaceutical industry experience to Zealand Pharma,” said Martin Nicklasson, Chairman of the board of directors.
  • From January 2020 until August 2023, Enrique Conterno served as the CEO and member of the board of directors at FibroGen, Inc.

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Retrieved on: 
Thursday, November 9, 2023
Hepatology, Virology, Immune system, University of Hong Kong, AASLD, Patient, HBV, Clinical trial, Division, Non-cirrhotic portal fibrosis, Liver, University, Cancer, Autoimmunity, CFBV, Vaccine, Pharmaceutical industry, HBsAg, Gastroenterology

WARMINSTER, Pa. and OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, and Barinthus Biotherapeutics plc (Nasdaq: BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer, today announced a late breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023. The poster contains preliminary data from the Phase 2a clinical trial (AB-729-202) combining Arbutus’ RNAi therapeutic, imdusiran (AB-729), with Barinthus Bio's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide analogue (NA) therapy.

Key Points: 
  • The poster contains preliminary data from the Phase 2a clinical trial (AB-729-202) combining Arbutus’ RNAi therapeutic, imdusiran (AB-729), with Barinthus Bio's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide analogue (NA) therapy.
  • Preliminary immunology data suggests HBV-specific T cell IFN-γ production is enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.
  • The preliminary safety data from this trial demonstrate that imdusiran and VTP-300 were both safe and well-tolerated.
  • Dr. Karen Sims, Chief Medical Officer of Arbutus Biopharma, commented, “Imdusiran consistently delivers compelling efficacy and safety data in multiple Phase 2a populations and combinations.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Monday, November 20, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Research, Science, Pharmaceutical, Sale, Heart, Southampton General Hospital, Pediatrics, Patient, Conference, Doctor of Philosophy, Viral, Webcast, Safety, RSV, Human, Respiratory system, MBBS, Federal, Chronic obstructive pulmonary disease, Texas A&M University, O'Driscoll (surname), Dean (education), Respiratory Medicine, Pharmacokinetics, University, FRCP, Fast Track, Asthma, Medication, Infection, FERS, Urinary tract infection, Virology, Ageing, Upper respiratory tract infection, Viral load, Clinical trial, Tax, HBV, FDA, Vaccine, Faculty, OMERS, HCV, State Administrative Expenses, Pharmaceutical industry, Life insurance, Cryptocurrency, Pfizer, Cantab, FIDSA, FAAP, Medicine, MD

(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.

Key Points: 
  • (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.
  • For the twelve months ended September 30, 2023, total revenue was $79.2 million compared to $86.2 million for the same period in 2022.
  • The decrease in the quarter and in year-over-year revenue is due to a decline in AbbVie’s sales of MAVYRET®/MAVIRET®.
  • Non-cash interest expense was $3.2 million for the three months ended September 30, 2023 and $5.1 million for the twelve months ended September 30, 2023.